Unlock instant, AI-driven research and patent intelligence for your innovation.
Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of compound and alkyl, which is applied in the field of disease treatment, can solve the problem that the activity of GnRH receptor antagonist is not described, etc.
Inactive Publication Date: 2014-11-26
BAYER IP GMBH
View PDF16 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0009] Spiroindoline derivatives are known in the art as pharmaceutical active ingredients and in the field of crop science as insecticides, but their activity as GnRH receptor antagonists has not been described so far
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0604] According to GP 9.1, 250 mg (0.62 mmol) of intermediate F.3 and 105 mg (0.74 mmol, 1.2 eq) of 1-(3-chloro Pyridin-2-yl)methanamine (CAS No. [500305-98-6]) was reacted with 280 mg (0.74 mmol, 1.2 equiv) of HATU in 10 mL DMF to yield 300 mg (84%) of the desired amide. 1 H-NMR (300MHz, DMSO-d6): chemical shift [ppm]=-0.02(d, 1H), 0.97-1.08(m, 1H), 1.25(d, 3H), 1.67(d, 1H), 1.96- 2.08(m, 1H), 3.32-3.50(m, 3H), 3.79-3.87(m, 1H), 4.50(q, 1H), 4.63(d, 2H), 7.33(dd, 1H), 7.35-7.41( m, 2H), 7.54 (d, 1H), 7.76 (d, 1H), 7.81 (dd, 1H), 7.87-7.92 (m, 3H), 8.44 (dd, 1H), 8.80 (t, 1H). UPLC-MS(ESI+): [M+H] + =530 / 532 (chlorine isotope pattern).
[0605] The enantiomers of the racemic material of Example 1 were analyzed by chiral preparative HPLC (System: Dionex: Pump P 580, Gilson: Liquid Handler 215) , Nuoer Company (Knauer...
Embodiment 11
[0606] Example 1.1: R t =17.81min;
Embodiment 12
[0607] Example 1.2: R t =23.01min;
[0608] Table 1 Applying the indicated general procedures, the following examples (3 to 11) were prepared in analogy to example 1 starting from intermediate F.3 and commercially available amines. Example 2 was prepared from intermediate C.5 according to the given procedure.
[0615] With GP 10: Dissolve 2.70 g (5.60 mmol) of intermediate C.1 in 40 mL 1,4-dioxane (containing 0.1 mL water) and add 2.38 g (3 equiv.) of 2-chlorobenzyl Amine (CAS No. [89-97-4]), 1.48 g (1 equivalent) of molybdenum hexacarbonyl, 1.78 g (3 equivalents) of sodium carbonate, 162 mg (0.1 equivalent) of tri-tert-butylphosphonium tetrafluoroborate and 126 mg (0.1 equivalent) palladium(II) acetate. The mixture was heated to reflux for 18h (bath temperature wa...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and / or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selded from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reprodudive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
Description
technical field [0001] The present invention relates to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists, to pharmaceutical compositions comprising the spiroindoline derivatives of the present invention, and to methods for breastfeeding in need thereof. Methods of administering the spiroindoline derivatives of the invention to animals, especially humans, for the treatment of disorders. Background technique [0002] Gonadotropin-releasing hormone (GnRH) is a decapeptide released by the hypothalamus (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ), also known as luteinizing hormone-releasing hormone (LHRH). GnRH acts on the pituitary gland to stimulate the biosynthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH released by the pituitary gland is responsible for regulating gonadal steroid production in both sexes, late ovarian follicle development and ovulation in female mammals, and FSH regulates ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More